Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202302033591i

Article Source : PR Newswire
Link : https://www.prnewswire.com/news-releases/qurient-co-ltd-and-tb-alliance-announce-exclusive-license-agreement-for-telacebec-q203-a-new-anti-tuberculosis-agent-301738149.html

Article Source : 바이오스펙테이터
Link : http://www.biospectator.com/view/news_view.php?varAtcId=18181

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20230202005011/en/Qurient-Announces-Dosing-of-First-Patient-in-Q702-in-Combination-with-KEYTRUDA%C2%AE-in-a-Phase-1b2-Clinical-Study-for-the-Treatment-of-Patients-with-Solid-Tumors

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202301193813i

Article Source : 머니투데이
Link : https://news.mt.co.kr/mtview.php?no=2022120109525454587

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20221123005365/en/Qurient-Announces-Dosing-of-First-Patient-in-Q901-Phase-12-Clinical-Study-for-the-Treatment-of-Patients-with-Solid-Tumors

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202210316313i

Article Source : 약업신문
Link : https://www.yakup.com/news/index.html?mode=view&cat=12&nid=274957

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202210055579i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202209278442i

큐리언트는 선택적 CDK7 억제제인 Q901과 MSD의 항PD-1 면역항암제 키트루다®(KEYTRUDA® – 성분명: 펨브롤리주맙)의 병용요법에 대한 임상연구를 위해 글로벌 제약회사 MSD(미국 머크)와 공동개발계약을 체결했다고 14일 밝혔다. 본 계약은 MSD의 항PD-1 면역항암제 키트루다®와 큐리언트의 선택적....

● Q901 is a novel highly selective CDK7 inhibitor ● Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT 05394103) ● The p....

큐리언트는 면역항암제 'Q702'와 키트루다의 병용요법에 대한 임상 1b·2상을 식품의약품안전처로부터 승인받았다고 6일 밝혔다. 지난 2월 미국 식품의약국(FDA)에도 같은 임상계획을 제출했다. 큐리언트와 미국 머크(MSD)는 공동 임상팀을 구성해 임상계획을 수립했다. 미국과 한국에서 142명의 환자를 대상으로 10....